Pharmacokinetics and Tolerability of Nasal Versus Intravenous Midazolam in Healthy Dutch Volunteers: A Single-Dose, Randomized-Sequence, Open-Label, 2-Period Crossover Pilot Study

Clinical Therapeutics

Volumn 33, Issue 12, 2011, Pages 2022-2028

  Veldhorst Janssen, Nicole M L ^a   Fiddelers, Audrey A A ^a   van der Kuy, Paul Hugo M ^b   Theunissen, H Maurice S ^a   de Krom, Marc C T F M ^a   Neef, Cees ^a,c   Marcus, Marco A E ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Zuyderland Medical Centre   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Intranasal; Midazolam; Pharmacokinetics; Pilot study

Indexed keywords

MIDAZOLAM;

ADULT; ALERTNESS; AMNESIA; AREA UNDER THE CURVE; ARTICLE; BITTER TASTE; BLOOD ANALYSIS; BLURRED VISION; BURNING SENSATION; CROSSOVER PROCEDURE; DIPLOPIA; DIZZINESS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; IRRITABILITY; MALE; MAXIMUM PLASMA CONCENTRATION; NASAL PRURITUS; NORMAL HUMAN; PAIN; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SWEATING; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, INTRANASAL; ADULT; ANTICONVULSANTS; CROSS-OVER STUDIES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDAZOLAM; MIDDLE AGED; NASAL SPRAYS; NETHERLANDS; PILOT PROJECTS;

EID: 83455195479     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.10.012     Document Type: Article

References (34)

1. Vespa P.M., McArthur D.L., Xu Y., et al. Nonconvulsive seizures after traumatic brain injury are associated with hippocampal atrophy. Neurology 2010, 75:792-798.
2. Scott R.C., Besag F.M., Neville B.G. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet 1999, 353:623-626.
3. Betts T. Epilepsy, Psychiatry and Learning Difficulty 1998, The Livery House, M. London.
4. Lahat E., Goldman M., Barr J., et al. Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study. BMJ 2000, 321:83-86.
5. Wermeling D.P. Intranasal delivery of antiepileptic medications for treatment of seizures. Neurotherapeutics 2009, 6:352-358.
6. Wermeling D.P., Record K.A., Kelly T.H., et al. Pharmacokinetics and pharmacodynamics of a new intranasal midazolam formulation in healthy volunteers. Anesth Analg 2006, 103:344-349.
7. Knoester P.D., Jonker D.M., Van Der Hoeven R.T., et al. Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. Br J Clin Pharmacol 2002, 53:501-507.
8. Beran R.G. An alternative perspective on the management of status epilepticus. Epilepsy Behav 2008, 12:349-353.
9. Kendall J.L., Reynolds M., Goldberg R. Intranasal midazolam in patients with status epilepticus. Ann Emerg Med 1997, 29:415-417.
10. O'Regan M.E., Brown J.K., Clarke M. Nasal rather than rectal benzodiazepines in the management of acute childhood seizures?. Dev Med Child Neurol 1996, 38:1037-1045.
11. Scheepers M., Scheepers B., Clarke M., et al. Is intranasal midazolam an effective rescue medication in adolescents and adults with severe epilepsy?. Seizure 2000, 9:417-422.
12. Scheepers M., Scheepers B., Clough P. Midazolam via the intranasal route: an effective rescue medication for severe epilepsy in adults with learning disability. Seizure 1998, 7:509-512.
13. Bhattacharyya M., Kalra V., Gulati S. Intranasal midazolam vs rectal diazepam in acute childhood seizures. Pediatr Neurol 2006, 34:355-359.
14. Burstein A.H., Modica R., Hatton M., et al. Pharmacokinetics and pharmacodynamics of midazolam after intranasal administration. J Clin Pharmacol 1997, 37:711-718.
15. Loftsson T., Gudmundsdottir H., Sigurjonsdottir J.F., et al. Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray. Int J Pharm 2001, 212:29-40.
16. Lugo R.A., Fishbein M., Nahata M.C., Lininger B. Complication of intranasal midazolam. Pediatrics 1993, 92:638.
17. Bjorkman S., Rigemar G., Idvall J. Pharmacokinetics of midazolam given as an intranasal spray to adult surgical patients. Br J Anaesth 1997, 79:575-580.
18. Dale O., Nilsen T., Loftsson T., et al. Intranasal midazolam: a comparison of two delivery devices in human volunteers. J Pharm Pharmacol 2006, 58:1311-1318.
19. Gudmundsdottir H., Sigurjonsdottir J.F., Masson M., et al. Intranasal administration of midazolam in a cyclodextrin based formulation: bioavailability and clinical evaluation in humans. Pharmazie 2001, 56:963-966.
20. Wermeling D.P., Record K.A., Archer S.M., Rudy A.C. A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation. Epilepsy Res 2009, 83:124-132.
21. Haschke M., Suter K., Hofmann S., et al. Pharmacokinetics and pharmacodynamics of nasally delivered midazolam. Br J Clin Pharmacol 2010, 69:607-616.
22. Ivaturi V.D., Riss J.R., Kriel R.L., Cloyd J.C. Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers. Acta Neurol Scand 2009, 120:353-357.
23. Humbert H., Cabiac M.D., Dubray C., Lavene D. Human pharmacokinetics of dihydroergotamine administered by nasal spray. Clin Pharmacol Ther 1996, 60:265-275.
24. Veldhorst-Janssen N., Van der Kuy P.-H., Neef C., et al. Optimalisation of intranasal midazolam. Anesthesiology 2006, 105:A628.
25. Dandliker W.B., Kelly R.J., Dandliker J., Farquahar J., Levin J. Fluorescence polarization immunoassay. Theory and experimental method. Immunochemistry 1973, 10:219-227.
26. Proost J.H., Meijer D.K. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992, 22:155-163.
27. Jelliffe R.W., Schumitzky A., Bayard D., et al. Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, Bayesian feedback and individualised target goals. Clin Pharmacokinet 1998, 34:57-77.
28. Jelliffe R.W., Schumitzky A., Van Guilder M., et al. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit 1993, 15:380-393.
29. Hardman J., Limbird L., Gilman A. Goodman & Gilman's The Pharmacological Basis of Therapeutics 2001, McGraw-Hill, New York, NY. 10th ed.
30. Bonate P.L. A brief introduction to Monte Carlo simulation. Clin Pharmacokinet 2001, 40:15-22.
31. De Haan G.J., Van der Geest P., Doelman G., et al. A comparison of midazolam nasal spray and diazepam rectal solution for the residential treatment of seizure exacerbations. Epilepsia 2010, 51:478-482.
32. Seo K.A., Bae S.K., Choi Y.K., et al. Metabolism of 1'- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7. Drug Metab Dispos 2010, 38:2007-2013.
33. Spier L., Wright I., Saylor L. A new method for determining the circulation time throughout the vascular system. Am Heart J 1936, 12:511-520.
34. Jensen M.P., Karoly P., Braver S. The measurement of clinical pain intensity: a comparison of six methods. Pain 1986, 27:117-126.